• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Orgenesis Inc. (Amendment)

    9/7/23 3:02:42 PM ET
    $ORGS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORGS alert in real time by email
    SC 13G/A 1 sc13ga110871003_09072023.htm

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 1)1

     

    Orgenesis, Inc.

     (Name of Issuer)

    Common Stock, par value $0.01 per share

     (Title of Class of Securities)

    68619K204

     (CUSIP Number)

    August 31, 2023

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 68619K204

     

      1   NAME OF REPORTING PERSON  
             
            JACOB SAFIER  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            UNITED STATES  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         4,734,860  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         -0-  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              4,734,860  
        8   SHARED DISPOSITIVE POWER  
               
              -0-  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            4,734,860  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            15.4%  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    2

    CUSIP No. 68619K204

      1   NAME OF REPORTING PERSON  
             
            NEW DIMENSIONS TRADING LTD.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            CAYMAN ISLANDS  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         2,734,860  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         -0-  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              2,734,860  
        8   SHARED DISPOSITIVE POWER  
               
              -0-  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            2,734,860  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            8.9%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 68619K204

    Item 1(a).Name of Issuer:

    Orgenesis Inc. (the “Issuer”).

    Item 1(b).Address of Issuer’s Principal Executive Offices:

    Orgenesis Inc.
    20271 Goldenrod Lane
    Germantown, MD 20876

    Item 2(a).Name of Person Filing:
    Item 2(b).Address of Principal Business Office or, if None, Residence:
    Item 2(c).Citizenship:

    New Dimensions Trading Ltd. (“New Dimensions”)
    c/o The Wolfson Group
    One State Street Plaza, 29th Floor
    New York, NY 10004
    Citizenship: Cayman Islands

    Jacob Safier
    c/o The Wolfson Group
    One State Street Plaza, 29th Floor
    New York, NY 10004
    Citizenship: United States

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

    Item 2(d).Title of Class of Securities:

    Common Stock, par value $0.01 per share (the “Shares”).

    Item 2(e).CUSIP Number:

    68619K204

    4

    CUSIP No. 68619K204

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership.
    (a)Amount beneficially owned:

    As of the date hereof:

    New Dimensions Trading Ltd. beneficially owned 2,734,860 Shares.

    Jacob Safier, as the portfolio manager of the Orgenesis investment by New Dimensions, may be deemed to beneficially own the Shares owned by New Dimensions and, therefore, may be deemed to beneficially own 4,734,860 Shares.

    (b)Percent of class:

    The following percentages are based upon 28,753,374 Shares outstanding, which is the total number of Shares reported as outstanding in the Issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 1, 2023, plus the 2,000,000 shares issued to Mr. Safier in the transaction described therein.

    As of the date hereof:

    New Dimensions beneficially owned 8.9% of the outstanding Shares.

    Jacob Safier may be deemed to beneficially own 15.4% of the outstanding Shares.

    5

    CUSIP No. 68619K204

    (c)Number of shares as to which such person has:
    (i)Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

    (ii)Shared power to vote or to direct the vote:

    0 Shares.

    (iii)Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    (iv)Shared power to dispose or to direct the disposition of:

    0 Shares.

    Item 5.Ownership of Five Percent or Less of a Class.

    Not Applicable.

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

    Item 8.Identification and Classification of Members of the Group.

    Not Applicable.

    Item 9.Notice of Dissolution of Group.

    Not Applicable.

    Item 10.Certifications.

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    6

    CUSIP No. 68619K204

    SIGNATURE

    After reasonable inquiry and to the best of his or her knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated: September 6, 2023

      New Dimensions Trading Ltd.
       
      By:

    /s/ Chana Edelstein

        Name: Chana Edelstein
        Title: Director

     

     

     

    /s/ Jacob Safier

      Jacob Safier

    7

    Get the next $ORGS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORGS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ORGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

      SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

      12/4/24 6:51:18 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Orgenesis Inc.

      SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

      12/4/24 6:50:26 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Orgenesis Inc. (Amendment)

      SC 13G/A - Orgenesis Inc. (0001460602) (Subject)

      2/14/24 8:16:04 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Malik Ariel claimed ownership of 1,200,000 shares (SEC Form 3)

      3 - Orgenesis Inc. (0001460602) (Issuer)

      3/18/25 4:06:38 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Vider Itzhak

      4 - Orgenesis Inc. (0001460602) (Issuer)

      12/16/24 2:42:24 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Adler Yaron

      4 - Orgenesis Inc. (0001460602) (Issuer)

      12/16/24 2:42:29 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Safier Jacob bought $16,883 worth of shares (30,000 units at $0.56) and sold $16,259 worth of shares (30,000 units at $0.54) (SEC Form 4)

      4 - Orgenesis Inc. (0001460602) (Issuer)

      12/4/24 6:48:38 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Safier Jacob bought $3,332 worth of shares (10,100 units at $0.33) (SEC Form 4)

      4 - Orgenesis Inc. (0001460602) (Issuer)

      2/14/24 9:32:21 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Safier Jacob bought $213,280 worth of shares (365,140 units at $0.58) (SEC Form 4)

      4 - Orgenesis Inc. (0001460602) (Issuer)

      2/14/24 9:31:52 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ORGS
    Leadership Updates

    Live Leadership Updates

    See more
    • Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support

      GERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the infrastructure of the advanced therapeutic POCare services and facilities supply business, Octomera. The appointment of Gerhard Bauer as the Vice President of Global Product Implementation at Octomera has been made to enhance the existing process development, regulatory, engineering, equipment, and data/technical service offering and POCare Center hubs. He is also an active contributor to the evolution of the flexible facilities format, Octomera Mobile Process Labs & Units (OMPULs) and network, which allow the

      9/6/23 7:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer

      GERMANTOWN, Md., July 13, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced the appointment of Elliot Maltz as Chief Financial Officer, effective September 1, 2023. Mr. Maltz succeeds Mr. Neil Reithinger, who is resigning following years of dedicated service and will remain with the Company until he completes his transition of duties, through September 1, 2023. Mr. Maltz brings 16 years of accounting and corporate finance experience working with public and private companies, specializing in the biotechnology, medical devic

      7/13/23 8:30:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Proactive news headlines including Altamira Gold, AIM ImmunoTech, QC Copper and Gold and Cloud Nine Education

      New York, March 08, 2021 (GLOBE NEWSWIRE) -- - Altamira Gold Corp (CVE:ALTA) (OTCPINK:EQTRF) (FRA:T6UP) reveals four high-grade gold and silver vein structures at its Apiacas project in Brazil click here - Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) teams with Dong-a University Hospital in South Korea and Cure Therapeutics to utilize its Mobile Processing Units and Labs, or OMPULs click here - QC Copper and Gold Inc (CVE:QCCU) (OTCMKTS:QCCUF) updates on Opemiska drill progress and names new independent director click here - AIM ImmunoTech Inc (NYSEAMERICAN:AIM) doses first healthy subject in intranasal Ampligen coronavirus study click here - Alpine 4 Technologies Inc (OTCQB:ALPP) say

      3/8/21 2:36:14 PM ET
      $TCON
      $ORGS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $ORGS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ORGS
    SEC Filings

    See more

    $ORGS
    Financials

    Live finance-specific insights

    See more
    • Orgenesis Provides Third Quarter 2024 Business Update

      GERMANTOWN, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCQX: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the third quarter ended September 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "Orgenesis is making significant progress in redefining accessibility to cell and gene therapies through our decentralized approach. This model is designed to expedite capacity setup, enhance production efficiency, and reduce treatment costs. We are dedicated to expanding our clinical initiatives and deepening gl

      11/13/24 8:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Commences Trading on OTCQX® Best Market

      Reports Plans to Reapply for Nasdaq Listing Announces Progress Advancing Decentralized Cell Processing Platform GERMANTOWN, Md., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today announced that its common stock will begin trading on the OTCQX® Best Market under the ticker symbol "ORGS" following its delisting from the Nasdaq Stock Market. The delisting resulted from the Company's failure to meet the required stockholders' equity threshold. Orgenesis plans to attempt to resolve the deficienc

      10/21/24 8:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Announces Reverse Stock Split

      GERMANTOWN, Md., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company") today announced that its Board of Directors has approved a 1-for-10 reverse stock split of the Company's common stock, par value $0.0001, which will be effective at 5:00 pm Eastern Time on September 24, 2024. The Company's common stock will continue to be traded on The Nasdaq Capital Market on a split-adjusted basis beginning on September 25, 2024, under the Company's existing trading symbol "ORGS". The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company's common stock for continued listing on The Nasdaq C

      9/23/24 7:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Orgenesis Inc.

      25-NSE - Orgenesis Inc. (0001460602) (Subject)

      5/8/25 5:21:49 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Inc. filed SEC Form 8-K: Other Events

      8-K - Orgenesis Inc. (0001460602) (Filer)

      4/22/25 4:30:38 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-K filed by Orgenesis Inc.

      NT 10-K - Orgenesis Inc. (0001460602) (Filer)

      4/1/25 4:05:18 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Provides Second Quarter 2024 Business Update

      GERMANTOWN, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the second quarter ended June 30, 2024. Vered Caplan, CEO of Orgenesis, stated, "After more than a decade of parallel efforts—on one hand, establishing robust capabilities in cell therapy production by initially serving the industry in a centralized manner and later integrating these capabilities into a decentralized platform, and on the other, forming partnerships through joint ve

      8/8/24 4:05:00 PM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

      GERMANTOWN, Md., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global leader in decentralizing cell and gene therapies (CGTs), today announced it has entered into a definitive agreement with MM OS Holdings L.P., an affiliate of Metalmark Capital Partners ("Metalmark"), for the acquisition of its approximate 25% stake in Octomera LLC ("Octomera"), the cell processing services subsidiary of the Company, thereby allowing the Company to have 100% ownership of this core strategic business unit. In exchange, Metalmark shall receive a royalty of 5% of the net revenue of Octomera's cell processing services, for the three calendar years 2025-2027,

      1/31/24 9:15:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Orgenesis Provides Business Update for Second Quarter of 2023

      Reports Progress in Advancing the Rollout of the POCare Platform and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the second quarter ended June 30, 2023. Vered Caplan, CEO of Orgenesis, said, "We are pleased to report revenue of approximately $7.0 million for the second quarter of 2023, which reflects the ongoing rollout of our POCare platform. We recently rebranded the POC Servic

      8/11/23 7:00:00 AM ET
      $ORGS
      Biotechnology: Pharmaceutical Preparations
      Health Care